|
 |
|
|||||||
|
|||||||||
Diabetes 51:2968-2974, 2002
© 2002 by the American Diabetes Association, Inc.
The Effect of Thiazolidinediones on Plasma Adiponectin Levels in Normal, Obese, and Type 2 Diabetic Subjects
1 Department of Medicine, Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, California
2 Veterans Administration San Diego Healthcare System, San Diego, California
3 Whittier Institute for Diabetes, La Jolla, California
4 GenSet Corporation, San Diego, California
5 Linco Research Inc., St. Charles, Missouri
The insulin-sensitizing effects of thiazolidinediones are thought to be mediated through peroxisome proliferator-activated receptor-
, a nuclear receptor that is highly abundant in adipose tissue. It has been reported that adipocytes secrete a variety of proteins, including tumor necrosis factor-
, resistin, plasminogen activator inhibitor-1, and adiponectin. Adiponectin is a fat cell-secreted protein that has been reported to increase fat oxidation and improve insulin sensitivity. Our aim was to study the effects of troglitazone on adiponectin levels in lean, obese, and diabetic subjects. Ten diabetic and 17 nondiabetic subjects (8 lean, BMI <27 kg/m2 and 9 obese, BMI >27 kg/m2) participated in the study. All subjects underwent an 80 mU · m-2 · min-1 hyperinsulinemic-euglycemic glucose clamp before and after 3 months’ treatment with the thiazolidinedione (TZD) troglitazone (600 mg/day). Fasting plasma glucose significantly decreased in the diabetic group after 12 weeks of treatment compared with baseline (9.1 ± 0.9 vs. 11.1 ± 0.9 mmol/l, P < 0.005) but was unchanged in the lean and obese subjects. Fasting insulin for the entire group was significantly lower than baseline (P = 0.02) after treatment. At baseline, glucose disposal rate (Rd) was lower in the diabetic subjects (3.4 ± 0.5 mg · kg-1 · min-1) than in the lean (12.3 ± 0.4) or obese subjects (6.7 ± 0.7) (P < 0.001 for both) and was significantly improved in the diabetic and obese groups (P < 0.05) after treatment, and it remained unchanged in the lean subjects. Baseline adiponectin levels were significantly lower in the diabetic than the lean subjects (9.0 ± 1.7 vs. 16.7 ± 2.7 µg/ml, P = 0.03) and rose uniformly in all subjects (12.2 ± 2.3 vs. 25.7 ± 2.6 µg/ml, P < 10–4) after treatment, with no significant difference detected among the three groups. During the glucose clamps, adiponectin levels were suppressed below basal levels in all groups (10.2 ± 2.3 vs. 12.2 ± 2.3 µg/ml, P < 0.01). Adiponectin levels correlated with Rd (r = 0.46, P = 0.016) and HDL cholesterol levels (r = 0.59, P < 0.001) and negatively correlated with fasting insulin (r = -0.39, P = 0.042) and plasma triglyceride (r = -0.61, P < 0.001). Our findings show that TZD treatment increased adiponectin levels in all subjects, including normal subjects in which no other effects of TZDs are observed. Insulin also appears to suppress adiponectin levels. We have confirmed these results in normal rats. These findings suggest that adiponectin can be regulated by obesity, diabetes, TZDs, and insulin, and it may play a physiologic role in enhancing insulin sensitivity.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. M. Rogers, N. Mashtalir, M. A. Rathod, O. Dubuisson, Z. Wang, K. Dasuri, S. Babin, A. Gupta, N. Markward, W. T. Cefalu, et al. Metabolically Favorable Remodeling of Human Adipose Tissue by Human Adenovirus Type 36 Diabetes, September 1, 2008; 57(9): 2321 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Bodary Links Between Adipose Tissue and Thrombosis in the Mouse Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2284 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Krusinova, M Klementova, J Kopecky, P Wohl, L Kazdova, P Mlejnek, M Pravenec, M Hill, and T Pelikanova Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects Eur. J. Endocrinol., October 1, 2007; 157(4): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Bergman, M.-A. Cornier, T. J. Horton, and D. H. Bessesen Effects of fasting on insulin action and glucose kinetics in lean and obese men and women Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1103 - E1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. G. Hanley, D. Bowden, L. E. Wagenknecht, A. Balasubramanyam, C. Langfeld, M. F. Saad, J. I. Rotter, X. Guo, Y.-D. I. Chen, M. Bryer-Ash, et al. Associations of Adiponectin with Body Fat Distribution and Insulin Sensitivity in Nondiabetic Hispanics and African-Americans J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2665 - 2671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, M. J. Quon, Y. Lee, S. H. Han, J. Y. Ahn, W.-J. Chung, J.-a Kim, and E. K. Shin Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients Eur. Heart J., June 2, 2007; 28(12): 1440 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Knudson, G. M. Dick, and J. D. Tune Adipokines and Coronary Vasomotor Dysfunction Experimental Biology and Medicine, June 1, 2007; 232(6): 727 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Semple, N. H. Halberg, K. Burling, M. A. Soos, T. Schraw, J. Luan, E. K. Cochran, D. B. Dunger, N. J. Wareham, P. E. Scherer, et al. Paradoxical Elevation of High-Molecular Weight Adiponectin in Acquired Extreme Insulin Resistance Due to Insulin Receptor Antibodies Diabetes, June 1, 2007; 56(6): 1712 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee Adiponectin levels in patients with intracranial atherosclerosis Neurology, May 29, 2007; 68(22): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Lely, J. A. Krikken, S. J. L. Bakker, F. Boomsma, R. P. F. Dullaart, B. H. R. Wolffenbuttel, and G. Navis Low Dietary Sodium and Exogenous Angiotensin II Infusion Decrease Plasma Adiponectin Concentrations in Healthy Men J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1821 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Menzaghi, V. Trischitta, and A. Doria Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease Diabetes, May 1, 2007; 56(5): 1198 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wiecek, M. Adamczak, and J. Chudek Adiponectin--an adipokine with unique metabolic properties Nephrol. Dial. Transplant., April 1, 2007; 22(4): 981 - 988. [Full Text] [PDF]
|
|
|
|
|
|
E. Lin, L. S. Phillips, T. R. Ziegler, B. Schmotzer, K. Wu, L. H. Gu, L. Khaitan, S. A. Lynch, W. E. Torres, C. D. Smith, et al. Increases in Adiponectin Predict Improved Liver, but Not Peripheral, Insulin Sensitivity in Severely Obese Women During Weight Loss Diabetes, March 1, 2007; 56(3): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Han, M. J. Quon, J.-a Kim, and K. K. Koh Adiponectin and Cardiovascular Disease: Response to Therapeutic Interventions J. Am. Coll. Cardiol., February 6, 2007; 49(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, F. B. Hu, and G. Curhan Serum Adiponectin and Renal Dysfunction in Men With Type 2 Diabetes Diabetes Care, February 1, 2007; 30(2): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frystyk, C. Berne, L. Berglund, K. Jensevik, A. Flyvbjerg, and B. Zethelius Serum Adiponectin Is a Predictor of Coronary Heart Disease: A Population-Based 10-Year Follow-Up Study in Elderly Men J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Sharma and B. Staels Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Faraj, G. Beauregard, E. Loizon, M. Moldes, K. Clement, Y. Tahiri, K. Cianflone, H. Vidal, and R. Rabasa-Lhoret Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin. J. Endocrinol., November 1, 2006; 191(2): 427 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shadid, C. D. A. Stehouwer, and M. D. Jensen Diet/Exercise Versus Pioglitazone: Effects of Insulin Sensitization with Decreasing or Increasing Fat Mass on Adipokines and Inflammatory Markers J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3418 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Retnakaran, A. J.G. Hanley, and B. Zinman Does Hypoadiponectinemia Explain the Increased Risk of Diabetes and Cardiovascular Disease in South Asians? Diabetes Care, August 1, 2006; 29(8): 1950 - 1954. [Full Text] [PDF]
|
|
|
|
|
|
G. K. Bandyopadhyay, J. G. Yu, J. Ofrecio, and J. M. Olefsky Increased Malonyl-CoA Levels in Muscle From Obese and Type 2 Diabetic Subjects Lead to Decreased Fatty Acid Oxidation and Increased Lipogenesis; Thiazolidinedione Treatment Reverses These Defects. Diabetes, August 1, 2006; 55(8): 2277 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Gordon and K. H. McKeever Oral and intravenous carbohydrate challenges decrease active ghrelin concentrations and alter hormones related to control of energy metabolism in horses J Anim Sci, July 1, 2006; 84(7): 1682 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Musri, H. Corominola, R. Casamitjana, R. Gomis, and M. Parrizas Histone H3 Lysine 4 Dimethylation Signals the Transcriptional Competence of the Adiponectin Promoter in Preadipocytes J. Biol. Chem., June 23, 2006; 281(25): 17180 - 17188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ong, J. Frystyk, A. Flyvbjerg, C. J. Petry, the Avon Longitudinal Study of Parents and Childre, A. Ness, and D. B. Dunger Sex-Discordant Associations With Adiponectin Levels and Lipid Profiles in Children. Diabetes, May 1, 2006; 55(5): 1337 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-a Kim, M. Montagnani, K. K. Koh, and M. J. Quon Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms Circulation, April 18, 2006; 113(15): 1888 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kubota, Y. Terauchi, T. Kubota, H. Kumagai, S. Itoh, H. Satoh, W. Yano, H. Ogata, K. Tokuyama, I. Takamoto, et al. Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways J. Biol. Chem., March 31, 2006; 281(13): 8748 - 8755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. S. Harris, E. W. Kelso, W. P. Flatt, T. J. Bartness, and H. J. Grill Energy Expenditure and Body Composition of Chronically Maintained Decerebrate Rats in the Fed and Fasted Condition Endocrinology, March 1, 2006; 147(3): 1365 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Bodary and D. T. Eitzman Adiponectin: Vascular Protection From the Fat? Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 235 - 236. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, M. J. Quon, S. H. Han, W.-J. Chung, J. Y. Ahn, J.-a Kim, Y. Lee, and E. K. Shin Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients Diabetes Care, February 1, 2006; 29(2): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Abbasi, S.-A. Chang, J. W. Chu, T. P. Ciaraldi, C. Lamendola, T. McLaughlin, G. M. Reaven, and P. D. Reaven Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R139 - R144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Szapary, L. T. Bloedon, F. F. Samaha, D. Duffy, M. L. Wolfe, D. Soffer, M. P. Reilly, J. Chittams, and D. J. Rader Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 182 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kobashi, M. Urakaze, M. Kishida, E. Kibayashi, H. Kobayashi, S. Kihara, T. Funahashi, M. Takata, R. Temaru, A. Sato, et al. Adiponectin Inhibits Endothelial Synthesis of Interleukin-8 Circ. Res., December 9, 2005; 97(12): 1245 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, S. H. Han, and M. J. Quon Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. LeBrasseur and N. B. Ruderman Why Might Thiazolidinediones Increase Exercise Capacity in Patients With Type 2 Diabetes? Diabetes Care, December 1, 2005; 28(12): 2975 - 2977. [Full Text] [PDF]
|
|
|
|
|
|
P. Balagopal, D. George, H. Yarandi, V. Funanage, and E. Bayne Reversal of Obesity-Related Hypoadiponectinemia by Lifestyle Intervention: A Controlled, Randomized Study in Obese Adolescents J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6192 - 6197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Madan Nonalcoholic fatty liver disease Can. Med. Assoc. J., September 27, 2005; 173(7): 734 - 735. [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, H. Holt, C. Wang, O. H. Hadid, and C. D. Byrne Expression of AdipoR1 In Vivo in Skeletal Muscle Is Independently Associated With Measures of Truncal Obesity in Middle-Aged Caucasian Men Diabetes Care, August 1, 2005; 28(8): 2058 - 2060. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Rossi, Y. B. Lombardo, J.-M. Lacorte, A. G. Chicco, C. Rouault, G. Slama, and S. W. Rizkalla Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R486 - R494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Bandyopadhyay, J. G. Yu, J. Ofrecio, and J. M. Olefsky Increased p85/55/50 Expression and Decreased Phosphotidylinositol 3-Kinase Activity in Insulin-Resistant Human Skeletal Muscle Diabetes, August 1, 2005; 54(8): 2351 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]
|
|
|
|
|
|
S. Fukuen, M. Iwaki, A. Yasui, M. Makishima, M. Matsuda, and I. Shimomura Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor {gamma} Agonistic Activity J. Biol. Chem., June 24, 2005; 280(25): 23653 - 23659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saraheimo, C. Forsblom, J. Fagerudd, A.-M. Teppo, K. Pettersson-Fernholm, J. Frystyk, A. Flyvbjerg, P.-H. Groop, and on behalf of the FinnDiane Study Group Serum Adiponectin Is Increased in Type 1 Diabetic Patients With Nephropathy Diabetes Care, June 1, 2005; 28(6): 1410 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, M. J. Quon, S. H. Han, J. Y. Ahn, D. K. Jin, H. S. Kim, D. S. Kim, and E. K. Shin Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes Hypertension, June 1, 2005; 45(6): 1088 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Kang, S. Y. Park, H. J. Kim, C. W. Ahn, M. Nam, B. S. Cha, S. K. Lim, K. R. Kim, and H. C. Lee The Influence of Adiponectin Gene Polymorphism on the Rosiglitazone Response in Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1139 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. W. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma Adipokines: molecular links between obesity and atheroslcerosis Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2031 - H2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Punyadeera, A. H G Zorenc, R. Koopman, A. J McAinch, E. Smit, R. Manders, H. A Keizer, D. Cameron-Smith, and L. J C van Loon The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle Eur. J. Endocrinol., March 1, 2005; 152(3): 427 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zacharova, J.-L. Chiasson, M. Laakso, and the STOP-NIDDM Study Group The Common Polymorphisms (Single Nucleotide Polymorphism [SNP] +45 and SNP +276) of the Adiponectin Gene Predict the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial Diabetes, March 1, 2005; 54(3): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sepilian and M. Nagamani Adiponectin Levels in Women With Polycystic Ovary Syndrome and Severe Insulin Resistance Reproductive Sciences, February 1, 2005; 12(2): 129 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 A M Diehl, Z P Li, H Z Lin, and S Q Yang Cytokines and the pathogenesis of non-alcoholic steatohepatitis Gut, February 1, 2005; 54(2): 303 - 306. [Full Text] [PDF]
|
|
|
|
 |
|